缺血性卒中后启动或恢复癌症治疗与临床结局
基于洛桑急性卒中登记2003至2021年数据,回顾分析260例活动性癌症的急性缺血性卒中患者,其中117例(45%)在3个月内启动或恢复癌症治疗。该治疗与3个月死亡率降低相关,12个月死亡率在倾向评分匹配后无显著差异,功能结局和脑血管复发风险无差异。
要点
- 活动性癌症的缺血性卒中患者中45%在3个月内启动或恢复癌症治疗。
- 启动或恢复癌症治疗与3个月死亡率降低相关,匹配后aHR 0.33。
- 功能结局和脑血管复发风险在两组间无显著差异。
核心结论
- 在近20年的卒中登记中,近半数活动性癌症患者卒中后3个月内启动或恢复癌症治疗,其中期死亡率降低,长期死亡率可能降低,功能结局和脑血管复发风险无差异。
研究设计与样本
- 回顾性分析洛桑急性卒中登记2003至2021年数据,纳入260例活动性癌症的急性缺血性卒中患者,比较3个月内启动或恢复癌症治疗者117例与未启动者,采用多变量回归和倾向评分匹配。
主要发现
- 260例活动性癌症患者中117例(45%)启动或恢复癌症治疗,中位年龄73岁(四分位距16-5),女性101例(39%),化疗是最常处方的癌症治疗。
- 较低的卒中严重程度与启动或恢复癌症治疗相关(aOR 0.93,95% CI 0.88-0.98)。
- 启动或恢复癌症治疗与3个月死亡率降低相关,倾向评分匹配前aHR 0.39(95% CI 0.28-0.56),匹配后aHR 0.33(95% CI 0.13-0.80)。
- 12个月死亡率在倾向评分匹配前aHR 0.81(95% CI 0.67-0.98),匹配后aHR 0.73(95% CI 0.45-1.20)。
- 3个月mRS评分aOR 0.96(95% CI 0.58-1.59),12个月mRS评分aOR 0.66(95% CI 0.36-1.19),3个月脑血管复发sHR 0.69(95% CI 0.28-1.69),12个月sHR 0.71(95% CI 0.28-1.78),匹配前后组间均相似。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Patients with acute ischemic stroke (AIS) and active cancer (AC) are at high risk of mortality and stroke recurrence. While cancer characteristics are key prognostic factors, the impact of initiating or resuming active cancer treatment (ACT) after AIS remains unclear. This study aimed to estimate the proportion of patients initiating or resuming ACT after AIS and evaluate their clinical characteristics and outcomes. METHODS: Using 2003-2021 data from the Acute STroke Registry and Analysis of Lausanne, we retrospectively analyzed patients with AC who initiated or resumed ACT within 3 months of index AIS vs those who did not. Exclusion criteria included patients with no or inactive cancer, insufficient data on ACT, and posthospitalization cancer diagnoses and those who died or entered palliative care before decisions on ACT. Outcomes included the modified Rankin Scale (mRS) score, mortality, and cerebrovascular recurrences at 3 and 12 months. Analyses comprised multivariable regressions, adjusting for prognostic variables, and propensity score matching (PSM). RESULTS: Among 6,686 patients with AIS, 260 had AC and met eligibility criteria, with 117 (45%) initiating or resuming ACT. The median age was 73 years (interquartile range 16-5); 101 (39%) were women. Chemotherapy was the most prescribed ACT. Lower stroke severity was associated with initiating or resuming ACT (adjusted odds ratio [aOR] 0.93, 95% CI 0.88-0.98). Initiating or resuming ACT was associated with reduced mortality at 3 months before (adjusted hazard ratio [aHR] 0.39, 95% CI 0.28-0.56) and after (aHR 0.33, 95% CI 0.13-0.80) PSM and at 12 months before PSM (aHR 0.81, 95% CI 0.67-0.98). Mortality at 12 months after PSM (aHR 0.73, 95% CI 0.45-1.20), mRS scores at 3 months (aOR 0.96, 95% CI 0.58-1.59) and 12 months (aOR 0.66, 95% CI 0.36-1.19), and cerebrovascular recurrence risk at 3 months (subdistribution hazard ratio [sHR] 0.69, 95% CI 0.28-1.69) and 12 months (sHR 0.71, 95% CI 0.28-1.78) remained similar across groups before and after PSM. DISCUSSION: In a nearly 2-decade stroke registry, almost half of the patients with AC initiated or resumed ACT within 3 months after AIS, with reduced medium-term and potentially long-term mortality but no differences in functional outcomes or cerebrovascular recurrence risk.
引用
- Costamagna G, Hottinger AF, Strambo D, et al. Initiating or Resuming Cancer Treatment After Ischemic Stroke and Clinical Outcomes. Neurology. 2025. PMID: 40080736. doi:10.1212/WNL.0000000000213458
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。